Treatment of Brca1-mutated tumor-bearing mice with AZD2281 was found to inhibit tumor growth alone and to potentiate the clinical effectiveness of DNA-damaging anticancer agents when used in a combined treatment regimen 10,11. The gene discussed is BRCA1; the disease is neoplasm.